Lecanemab

Key takeaways

Lecanemab belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Lecanemab to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Lecanemab from memory before moving on to harder problems.

Reference excerpt

Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of mild Alzheimer's disease. Lecanemab is an amyloid beta-directed antibody. It is given via intravenous infusion or subcutaneous injection. In clinical trials, it demonstrated small or no clinically significant efficacy in Alzheimer's disease. The most common side effects of lecanemab include headache, infusion-related reactions, and amyloid-related imaging abnormalities, a side effect known to occur with the class of antibodies targeting amyloid. Lecanemab was jointly developed by Eisai, Biogen, and Bioarctic.

Medical uses Lecanemab is indicated for the treatment of Alzheimer's disease in people who have mild cognitive impairment or mild dementia, but not in people who already have moderate or severe dementia.

Efficacy A 2026 meta-analysis suggests that lecanemab has no effect in the treatment of Alzheimer's disease. A 2026 Cochrane review found no effect or at best small effect.

Adverse effects Lecanemab may cause harmful adverse effects. Lecanemab may cause amyloid-related imaging abnormalities (ARIA). ARIA is often asymptomatic, but serious and life-threatening events rarely may occur. ARIA most commonly presents as temporary swelling of the brain that usually resolves over time and may be accompanied by small spots of bleeding in or on the surface of the brain, though some people may have symptoms such as headache, confusion, dizziness, vision changes, nausea and seizure. Compared to placebo, all doses of the drug caused accelerated brain shrinkage. However, one study indicates the brain volume reductions are consistent with amyloid plaque removal.

Pharmacology

Mechanism of action

Lecanemab is a humanized monoclonal antibody consisting of a humanized version of a mouse antibody, mAb158, that recognizes protofibrils and prevents amyloid beta deposition in animal models of Alzheimer's disease.

History In July 2022, the US Food and Drug Administration (FDA) accepted an application for accelerated approval for lecanemab. In September 2022, Biogen announced positive results from an ongoing phase III clinical trial. In November 2022, it was announced that the drug was a success in clinical trials and exceeded its goal in reaching primary endpoints.

The efficacy of lecanemab was evaluated in a double-blind, placebo-controlled, parallel-group, dose-finding study of 856 participants with Alzheimer's disease. Treatment was initiated in participants whose disease was in the stage of mild cognitive impairment or mild dementia and who had confirmed presence of amyloid beta pathology. Participants receiving the treatment showed significant dose- and time-dependent reduction of amyloid beta plaque: Those receiving the approved dose of lecanemab, 10 milligrams/kilogram every two weeks, had a statistically significant reduction in brain amyloid plaque from baseline to week 79 compared with those receiving a placebo, who had no reduction of amyloid beta plaque. The FDA approved lecanemab in January 2023 via the accelerated approval pathway for the treatment of Alzheimer's disease. The FDA granted the application for lecanemab fast track, priority review, and breakthrough therapy designations. The approval of Leqembi was granted to Eisai R&D Management Co., Ltd. In July 2023, the FDA converted lecanemab to traditional approval. The efficacy of lecanemab was evaluated using results from Study 301 (CLARITY AD), a phase III randomized, controlled clinical trial. Study 301 was a multicenter, randomized, double-blind, placebo-controlled, parallel-group study that enrolled 1,795 participants with Alzheimer's disease. Treatment was initiated in participants with mild cognitive impairment or mild dementia stage of disease and confirmed presence of amyloid beta pathology. Participants were randomized in a 1:1 ratio to receive placebo or lecanemab at a dose of 10 milligrams (mg)/kilograms (kg), once every two weeks. Lecanemab demonstrated a reduction of decline from baseline to 18 months on the primary endpoint, the Clinical Dementia Rating Scale Sum of Boxes score, compared to placebo. Statistically significant differences between treatment groups were also demonstrated on all secondary endpoints, which included the Alzheimer's Disease Assessment Scale Cognitive Subscale 14, and the Alzheimer's Disease Cooperative Study–Activities of Daily Living Scale for Mild Cognitive Impairment. In August 2025, the FDA approved a subcutaneous auto-injector form called "Leqembi Iqlik" for maintenance dosing after an initial series of infusions over 18 months.

Society and culture

Legal status Lecanemab was granted accelerated approval for medical use in the United States in January 2023, and traditional approval in July 2023. Lecanemab was approved for medical use in South Korea in May 2024, Mexico in December 2024,, the EU in April 2025, and Canada in October 2025.

Australia In October 2024, the Australian Therapeutic Goods Administration (TGA) decided not to register lecanemab. In December 2024, Eisai requested reconsideration of the decision, and the TGA confirmed its decision to not register lecanemab in March 2025.

Canada In October 2025, lecanemab was authorized in Canada. Due to its high cost (about US$26,000 per year), lecanemab was not included for coverage in the public health system. It was added to the prescription drug list in December 2025.

European Union In July 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended the refusal of the marketing authorization for lecanemab. The manufacturer requested re-examination. In November 2024, after re-examining its initial opinion, the CHMP recommended granting a marketing authorization to lecanemab (Leqembi) for treating mild cognitive impairment (memory and thinking problems) or mild dementia due to Alzheimer's disease (early Alzheimer's disease) in people who have only one or no copy of ApoE4, a certain form of the gene for the protein apolipoprotein E. Lecanemab was authorized for medical use in the European Union in April 2025.

… excerpt ends here. Continue reading the full article.

Worked examples

Example 1 — a first encounter with Lecanemab

Start with the simplest possible case. Write down what Lecanemab claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Lecanemab before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Lecanemab ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Lecanemab

In research: Lecanemab appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Lecanemab in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Lecanemab is common in secondary-school and first-year university syllabi. It links to neighbouring topics Anti-amyloid monoclonal antibodies, Orphan drugs, so understanding it makes those chapters shorter.
In everyday life: Look for Lecanemab outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

How to study Lecanemab in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Lecanemab means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Lecanemab out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Lecanemab in simple terms?

Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of mild Alzheimer's disease. Lecanemab is an amyloid beta-directed antibody.

Why does Lecanemab matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Lecanemab?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Lecanemab.